Former British Army Chief Calls for Easing Regulations on MDMA to Treat Veterans with PTSD
The former head of Britain's military has made a call for change in a bid to help veterans who are struggling with post-traumatic stress disorder (PTSD). Sir Nick Carter, the chief of the defence staff until 2021, argues that current regulations make it unaffordable for clinical trials on MDMA-assisted therapy, which have shown promising results in treating the condition.
Currently, the cost of testing medical-grade MDMA is around Β£10,000 per gram, compared to just Β£40 for an illicit purchase. Carter believes this discrepancy makes it difficult to recruit participants for studies and limits the potential benefits of this treatment for veterans who are often struggling with debilitating symptoms such as hyper-vigilance, hyper-arousal, and flashbacks.
The former general also points out that existing treatments for PTSD have had limited success in addressing these specific issues. Carter is now calling on the government to reduce the restrictions on MDMA, which could pave the way for more trials on this treatment.
This move has the potential to go beyond veterans, with experts suggesting it could help police officers and workers in emergency services who may also be affected by PTSD. A charity backed by Carter is currently raising funds for a further trial of MDMA-assisted therapy at the University of Cambridge.
One person hoping to benefit from this new treatment is Martin Wade, a former lawyer with the British army who was deployed to Afghanistan and struggled with PTSD after his deployment. He believes that the trials "really offer some hope to veterans" and has spoken about how he was able to find some relief through art therapy. However, Wade also highlighted the need for more help for those struggling with PTSD.
The issue of PTSD is a growing concern in the UK, particularly among military veterans who have seen action in Iraq and Afghanistan. The government's willingness to explore new treatments such as MDMA-assisted therapy could be a major step forward in addressing this complex condition.
The former head of Britain's military has made a call for change in a bid to help veterans who are struggling with post-traumatic stress disorder (PTSD). Sir Nick Carter, the chief of the defence staff until 2021, argues that current regulations make it unaffordable for clinical trials on MDMA-assisted therapy, which have shown promising results in treating the condition.
Currently, the cost of testing medical-grade MDMA is around Β£10,000 per gram, compared to just Β£40 for an illicit purchase. Carter believes this discrepancy makes it difficult to recruit participants for studies and limits the potential benefits of this treatment for veterans who are often struggling with debilitating symptoms such as hyper-vigilance, hyper-arousal, and flashbacks.
The former general also points out that existing treatments for PTSD have had limited success in addressing these specific issues. Carter is now calling on the government to reduce the restrictions on MDMA, which could pave the way for more trials on this treatment.
This move has the potential to go beyond veterans, with experts suggesting it could help police officers and workers in emergency services who may also be affected by PTSD. A charity backed by Carter is currently raising funds for a further trial of MDMA-assisted therapy at the University of Cambridge.
One person hoping to benefit from this new treatment is Martin Wade, a former lawyer with the British army who was deployed to Afghanistan and struggled with PTSD after his deployment. He believes that the trials "really offer some hope to veterans" and has spoken about how he was able to find some relief through art therapy. However, Wade also highlighted the need for more help for those struggling with PTSD.
The issue of PTSD is a growing concern in the UK, particularly among military veterans who have seen action in Iraq and Afghanistan. The government's willingness to explore new treatments such as MDMA-assisted therapy could be a major step forward in addressing this complex condition.